EP2621932A4 - Tetrazyklische heterozyklus-verbindungen zur behandlung von hepatitis-c-virus-infektionen - Google Patents

Tetrazyklische heterozyklus-verbindungen zur behandlung von hepatitis-c-virus-infektionen

Info

Publication number
EP2621932A4
EP2621932A4 EP11828123.7A EP11828123A EP2621932A4 EP 2621932 A4 EP2621932 A4 EP 2621932A4 EP 11828123 A EP11828123 A EP 11828123A EP 2621932 A4 EP2621932 A4 EP 2621932A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
treatment
virus infection
heterocyclic compounds
tetracyclic heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11828123.7A
Other languages
English (en)
French (fr)
Other versions
EP2621932A1 (de
Inventor
Michael P Dwyer
Kartik M Keertikar
Craig A Coburn
Hao Wu
Bin Hu
Bin Zhong
Chengren Zhang
Zhigang Dan
Ling Tong
Wensheng Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/077498 external-priority patent/WO2012040924A1/en
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of EP2621932A1 publication Critical patent/EP2621932A1/de
Publication of EP2621932A4 publication Critical patent/EP2621932A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11828123.7A 2010-09-29 2011-09-28 Tetrazyklische heterozyklus-verbindungen zur behandlung von hepatitis-c-virus-infektionen Withdrawn EP2621932A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/077498 WO2012040924A1 (en) 2010-09-29 2010-09-29 Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
US201061426738P 2010-12-23 2010-12-23
PCT/CN2011/080270 WO2012041227A1 (en) 2010-09-29 2011-09-28 Tetracyclic heterocycle compounds for treating hepatitis c viral infection

Publications (2)

Publication Number Publication Date
EP2621932A1 EP2621932A1 (de) 2013-08-07
EP2621932A4 true EP2621932A4 (de) 2014-03-26

Family

ID=45891961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11828123.7A Withdrawn EP2621932A4 (de) 2010-09-29 2011-09-28 Tetrazyklische heterozyklus-verbindungen zur behandlung von hepatitis-c-virus-infektionen

Country Status (2)

Country Link
EP (1) EP2621932A4 (de)
WO (1) WO2012041227A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
CN102869657A (zh) 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒感染的类似物
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2841095A1 (en) 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
KR102430183B1 (ko) 2014-09-26 2022-08-08 더 케무어스 컴퍼니 에프씨, 엘엘씨 아이소시아네이트 유도된 유기실란
CN104478877B (zh) * 2014-10-31 2016-08-24 广东东阳光药业有限公司 制备雷迪帕韦中间体的方法
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021928A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) * 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
WO2006046039A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
AU2008295483B2 (en) * 2007-08-29 2013-11-21 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and their use for treating or preventing viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021928A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012041227A1 *

Also Published As

Publication number Publication date
WO2012041227A1 (en) 2012-04-05
EP2621932A1 (de) 2013-08-07

Similar Documents

Publication Publication Date Title
EP2621932A4 (de) Tetrazyklische heterozyklus-verbindungen zur behandlung von hepatitis-c-virus-infektionen
EP2621931A4 (de) Tetrazyklische indolderivate zur behandlung von hepatitis-c-virus-infektionen
EP2744332A4 (de) Benzofuranverbindungen zur behandlung von hepatitis-c-virusinfektionen
EP2658857A4 (de) Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
EP2888240A4 (de) Verbindungen zur behandlung von paramoxyvirusinfektionen
EP2552203A4 (de) Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
EP2633051A4 (de) Hbv-behandlung
EP2385951A4 (de) Phosphoramidatderivate aus guanosin-nukleosidverbindungen zur behandlung von virusinfektionen
EP2558466A4 (de) Phosphonate mit reduzierter toxizität zur behandlung von virusinfektionen
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EP2516430A4 (de) Kondensierte trizyklische verbindungen und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
EP2503881A4 (de) Kondensierte trizyklische verbindungen und derivate davon zur behandlung von virenerkrankungen
EP2753618A4 (de) Heterocyclische substituierte benzofuranderivate und verwendungsverfahren dafür zur behandlung von viruserkrankungen
EP2807252A4 (de) Verfahren zur erhöhung der infektiosität von viren
EP2816054A4 (de) Makrocyclische verbindungen zur unterdrückung der replikation des hepatitis c-virus
EP2254582A4 (de) Verfahren zur behandlung von virusinfektionen
EP2632452A4 (de) Verbindungen und zusammensetzungen zur behandlung von krebs
EP2753611A4 (de) Substituierte benzofuranverbindungen und verfahren zu ihrer verwendung für die behandlung von virenerkrankungen
EP2782578A4 (de) Verfahren zur behandlung von hepatitis-c-virusinfektion mit quercetinhaltigen zusammensetzungen
EP2646043A4 (de) Neue cyclosporinderivate zur vorbeugung und behandlung von virusinfektionen
EP2953456A4 (de) Tetracyclische heterocyclische verbindungen sowie verfahren zur verwendung davon zur behandlung von virenerkrankungen
EP2534150A4 (de) Verfahren zur behandlung von vireninfektionen
EP2296654A4 (de) 8-hydroxychinolin-derivate zur behandlung von bösartigen hämatologischen erkrankungen
EP2341924A4 (de) Verfahren zur behandlung von hepatitis-c-virusinfektionen
EP2709619A4 (de) Verbindungen zur verwendung bei der behandlung von schleimhautentzündungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101ALI20140218BHEP

Ipc: C07D 493/22 20060101ALI20140218BHEP

Ipc: C07D 471/22 20060101ALI20140218BHEP

Ipc: C07D 491/22 20060101ALI20140218BHEP

Ipc: C07D 498/04 20060101AFI20140218BHEP

Ipc: A61K 31/4985 20060101ALI20140218BHEP

Ipc: C07D 471/04 20060101ALI20140218BHEP

Ipc: A61K 31/5365 20060101ALI20140218BHEP

Ipc: C07D 487/04 20060101ALI20140218BHEP

Ipc: A61P 31/14 20060101ALI20140218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140924